Aktiesnakken — Januar 2011
-
Gsk har et program for sponsoreret behandlinger
-
TOPO: Frågan är väl om ändå inte denna analysen är bättre: http://www3.redeye.se/medlemsanalys/37528
-
Vi har at gøre med uhelbredelige kræftpatienter så jeg vil lige anholde sprogbrugen "smagsprøver"
-
Der er ingen konkurrence til arzerra i den godkendte indikationer
-
Men tvivler på at der i de 1700 pts ikke befinder sig off label pts
-
Når NEO,MLI,MSI,CBA osv køber vws og der kun er Jyske og Danske til at spæde til, så sker der noget med kursen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind